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SHORT COMMUNICATION
Awareness and management of elevated blood pressure among human
immunodeficiency virus–infected adults receiving antiretroviral therapy in
urban Zambia: a call to action
Sophie Bauera,b, Mwanza Wa Mwanzab, Roma Chilengib, Charles B. Holmesb,c, Zude Zyambob,
Hansjakob Furrer a, Matthias Egger d, Gilles Wandelera,d and Michael J. Vinikoorb,e,f
aDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland; bCentre for Infectious Diseases
Research in Zambia, Lusaka, Zambia; cSchool of Medicine, Johns Hopkins University, Baltimore, USA; dInstitute of Social and Preventive
Medicine, University of Bern, Bern, Switzerland; eDepartment of Medicine, University of Alabama at Birmingham, Birmingham, USA;
fSchool of Medicine, University of Zambia, Lusaka, Zambia
ABSTRACT
The prevalence of high blood pressure (HBP) and hypertension (HTN), awareness of the diag-
noses, and use of anti-hypertensive drugs were examined among human immunodeficiency
virus (HIV)-infected individuals on antiretroviral therapy (ART) in Zambia’s capital Lusaka. Within a
prospective cohort based at two public sector ART clinics, BP was measured at ART initiation and
every 6 months thereafter as a routine clinic procedure. Predictors of HBP (systolic BP
≥140 mmHg or diastolic BP ≥90 mmHg) during one year on ART were analyzed using logistic
regression, and the proportion with HTN (2+ episodes of HBP >3 months apart) described. A
phone survey was used to understand patient awareness of HBP, use of anti-hypertensive drugs,
and history of cardiovascular events (CVE; myocardial infarction or stroke). Among 896 cohort
participants, 887 (99.0%) had at least one BP measurement, 98 (10.9%) had HBP, and 57 (6.4%)
had HTN. Increasing age (10-year increase in age: adjusted odds ratio [AOR] = 1.50; 95%
confidence interval [CI] 1.20–1.93), male sex (AOR = 2.33, 95% CI 1.43–3.80), and overweight/
obesity (AOR = 4.07; 95% CI 1.94–8.53) were associated with HBP. Among 66 patients with HBP,
35 (53.0%) reported awareness of the condition, and nine (25.7%) of these reported having had a
CVE. Only 14 (21.2%) of those reached reported ever taking an anti-hypertensive drug, and one
(1.5%) was currently on treatment. These data suggest that major improvements are needed in
the management of HBP among HIV-infected individuals in settings such as Zambia.
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Background
Human immunodeficiency virus (HIV)-infected indivi-
duals have an increased risk of cardiovascular disease
(CVD) compared to the general population [2]. CVD-
related mortality is anticipated to increase as HIV-
infected patients initiate antiretroviral therapy (ART) at
CD4+ counts >200 and opportunistic infections become
uncommon [3–5]. In sub-Saharan Africa, there are
numerous challenges in the diagnosis and control of
hypertension (HTN), including low awareness among
patients and providers [6], overcrowded clinics, and lim-
ited opportunities for HTN screening [7]. Care and
treatment programs for HIV present a promising plat-
form to address HTN because care is provided long-
itudinally, and most clinics provide pharmacy,
laboratory, and clinical services as well as counseling
and health education [8]. In Zambia, where 12.5% of
adults are HIV-positive[9] and adult HTN among the
general population is estimated at 35% [10], the Ministry
of Health (MoH) recommends routine monitoring of
blood pressure (BP) as part of HIV care [11]. This
study sought to describe the prevalence, awareness, and
management of high BP (HBP) in patients attending
public-sector HIV clinics in Lusaka, Zambia.
Methods
A prospective HIV cohort was established in 2013 at two
public-sector clinics in Lusaka to investigate viral hepa-
titis–HIV co-infection [12,13]. From 1 October 2013, to
15 August 2014, HIV-infected and ART-eligible adults
(>18 years old) who initiated ART under MoH guide-
lines were prospectively enrolled [11]. From 16 August
2014 to 30 September 2015, enrollment was restricted to
those with HIV–hepatitis B virus co-infection (defined
by a positive hepatitis B surface antigen test).
Data collection mirrored that of the clinics, including
baseline assessment of demographic characteristics,
World Health Organization HIV clinical stage, and
CD4+ count. At ART initiation, potential non-commu-
nicable disease (NCD) risk factors were assessed includ-
ing bodymass index, current smoking status (yes/no and
pack-years among current smokers), alcohol consump-
tion (based on the Alcohol Use Disorders Identification
CONTACT Michael J. Vinikoor mjv3@uab.edu Division of Infectious Diseases, University of Alabama at Birmingham, #215 Tinsley Harrison
Tower, 1530 3rd Avenue South, Birmingham, AL 35294-0006, USA
GLOBAL HEALTH ACTION, 2017
VOL. 10, 1359923
https://doi.org/10.1080/16549716.2017.1359923
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nl
oa
de
d 
by
 [E
-L
ibr
ary
 In
se
l] 
at 
00
:50
 16
 A
ug
us
t 2
01
7 
Test-Consumption), and BP. BP was measured once in
the upper arm by a nurse or lay health worker using a
battery-operated automated monitoring device (Omron
brand, Kyoto, Japan) and medium-sized adult cuff after
the patient was seated for 2–4 min. The preferred ART
regimen at the time was fixed-dose combination of efa-
virenz, emtricitabine, and tenofovir disoproxil fumarate.
At 24- and 48-week follow-up visits, BP was re-measured
per clinic practice. Medications for HTN are free of
charge in the outpatient departments of health facilities
in Zambia. However, clinicians in ART clinic may also
prescribe these drugs.
During December 2015 to January 2016, a phone
survey was conducted of all cohort participants with
HBP, defined as elevated systolic BP ≥140 mmHg or
diastolic BP ≥90 mmHg, during the first year on ART.
HTN was defined as elevated systolic or diastolic BP
measurements on two separate visits at least 3 months
apart. Pharmacy records were also extracted for any anti-
hypertensive, any diabetic drugs, or any documented
CVD events. Using the phone number on file in the
clinic, a nurse made up to five attempted calls to patients
with HBP over several different days and times. If
reached, using a standardized data collection tool, the
nurse asked a series of questions in the local language
(Nyanja, Bemba, or English) concerning patient aware-
ness and history ofHBP (including location of diagnosis).
Prior or current receipt of anti-hypertensive drugs, his-
tory of other CVD risk factors (diabetes) or cardiovascu-
lar events (CVE; myocardial infarction or stroke), and
family history ofHTNwere ascertained by patient report.
Factors associated with having HBP in the cohort
were assessed using a stepwise logistic regression
model with a backward selection algorithm. The
removal probability was set at 0.2 using likelihood
ratio test. Among HBP patients who participated in
the phone survey, the proportion with awareness of
the condition and the proportion who ever took anti-
hypertensive drugs were described, as well as the num-
ber who self-reported a history of CVE. Stata v13
(StataCorp, College Station, TX) was used for analysis.
The University of Zambia Biomedical Research Ethics
Committee approved the study (protocol # 010-08-12;
initial approval date 9 November 2012).
Results
Among 896 cohort participants, the median age was
34 (interquartile range [IQR] 29–40 years), 467
(52.1%) were women, and the median CD4+ count
at ART initiation was 227 cells/mm3 (IQR 118–337
cells/mm3). At baseline, 102 (11.6%) patients were
overweight or obese, and this was more common
among women than men (17.6% vs. 5.0%;
p < 0.001). Men were more likely to report smoking
(21.7% vs. 2.4%; p < 0.001) at baseline compared to
women. Patient demographics were similar between
2013–2014 and 2014–2015. During the first year on
ART, 60 (6.7%) were lost to follow-up.
BP was measured for 883 (98.5%) at baseline, for 751
(97.9%) of the 767 with retention at the 6-month visit,
and for 604 (84.8%) of the 712 with retention at the 12-
month visit; 770 (85.8%) had at least two measurements.
During the first year on ART, 98 (10.9%) patients had
documentedHBP on at least one occasion, and 57 (6.4%)
had HTN. Retention at 1 year was similar between
patients with HBP and normal BP at baseline (86.8%
vs. 80.9%; p = 0.29). Increasing age (for each 10-year
increase in age [1]: adjusted odds ratio [AOR] = 1.50;
95% confidence interval [CI] 1.20–1.93), male sex
(AOR = 2.33, 95% CI 1.43–3.80), and overweight/obesity
(AOR = 4.07; 95% CI 1.94–8.53) were associated with
increased odds of HBP. Pre-ART CD4+ count was not
associated with HBP (Table 1). Repeat analysis using
HTN as the outcome identified similar risk factors
(data not shown). A sensitivity analysis performed after
exclusion of HIV–HBV patients recruited after August
2015 had similar results.
During the phone survey, 92 patients with HBP were
called. Of these, 66 (71.7%) were reached, and 26 were
not reached because there was no answer (n = 15), the
line was inactive/invalid (n = 5), the patient had died
(n = 3), or there was no documented phone number
(n = 3). Thirty-five (53.0%) patients reported being aware
of having HBP, and awareness increased with increased
number of HBP measurements (35.3% for one and 60%
for two to three elevated readings).Most patients (62.9%)
became aware of HBP at the ART clinic (62.9%), while
others were diagnosed at the clinic’s outpatient depart-
ment (22.9%) or at a referral hospital (14.3%). The diag-
nosis of HBPwas primarily communicated to patients by
nurses (60.0%) and less commonly by a physician
(25.7%) or a clinical officer (14.3%).
Although many patients were aware of having
HBP, only 14 (21.2%) had ever taken an anti-hyper-
tensive drug, and only one person was currently tak-
ing a drug for treatment of HTN (Figure 1).
Nifedipine (n = 4) and furosemide (n = 3) were the
most commonly taken medicines for HBP, but the
majority (n = 7) could not recall the names of the
drugs they had taken. Review of the HIV clinic
records for patients with HBP did not reveal any
additional anti-hypertensive prescription or CVE
information. Of the 66 patients reached by phone,
24 (36.4%) by either file review or self-report had at
least one other known CVD risk factor, and nine
(13.6%) self-reported a history of CVE.
Discussions
To the authors’ knowledge, this is the first study on
patient awareness of HBP and its management in an
HIV care setting in Zambia. Routinely collected HIV
data were augmented using a phone survey, which is
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an efficient way to assess and distribute public-health
information [14]. Approximately 10% had HBP, with
6.4% meeting the criteria for HTN. However, patient
awareness of HBP was relatively low (53.0%). Receipt
of anti-hypertensive drugs was rare, even among the
13.5% of individuals with reported CVEs, suggesting
that major improvements are needed in the manage-
ment of HTN among HIV-infected individuals in
settings such as Zambia.
BP was measured regularly at clinic visits and
documented in files, suggesting that screening for
HTN in HIV care settings is feasible. The data on
HBP build on other studies [15,16] and were signifi-
cantly lower than a household survey in Lusaka (35%)
[10], possibly because of immune suppression (med-
ian CD4+ count = 227) and malnourishment (29%
had a body mass index <18.5 kg/m2) that were com-
mon in the cohort. HBP tends to become more com-
mon after ART initiation and may cause HTN [4].
Consistent with other African data [17], only half of
patients were aware of having HBP, and similar to
our study at rural outpatient clinics in Zambia [18],
few patients took anti-hypertensive drugs. Challenges
to HIV-NCD integration range from low patient and
provider awareness, education, and training to struc-
tural and logistic barriers [7,19].
This study has several limitations. In the primary
analysis, HBP was defined as a single elevated measure-
ment, and BP was measured only once at each time
point. This may have inflated the number of patients
truly needing treatment, as only 58% of patients with
HBP were confirmed to have HTN. Data on currently
anti-hypertensive medications were not well documen-
ted in ART clinic. Therefore, HTN patients on treatment
who did not have HBP during the cohort could have
been overlooked. However, this would have been
uncommon because so few patients in the phone survey
reported taking BP-lowering drugs. Self-reported phone
survey data were subject to recall bias andmay have been
inaccurate. Clinical adjudication of patient-reported
CVEs would have strengthened the data, as it is acknowl-
edged that in Zambia, health literacy is low, and reported
Table 1. Factors associatedwith high blood pressure amongHIV-infected adults taking antiretroviral therapy in Lusaka, Zambia (N= 896)
Crude odds ratio (95% CI) Adjusted odds ratio (95% CI)
Age, per 10-year increase 1.62 (1.30–2.02) 1.52 (1.20–1.93)
Male sex 2.00 (1.30–3.07) 2.33 (1.43–3.80)
Monthly household income
<K500.00 Reference
≥K500.00 1.40 (0.84–2.32)
Education level completed
No formal education Reference
Grade 1–6 0.98 (0.30–3.15)
Grade 7–9 1.32 (0.45–3.83)
Grade 10 and above 1.58 (0.53–4.73)
WHO clinical stage
1 or 2 Reference
3 or 4 0.99 (0.65–1.51)
Body mass index
<18.5 Reference Reference
18.5–25 1.69 (0.97–2.93) 1.55 (0.88–2.74)
>25 3.65 (1.86–7.15) 4.07 (1.94–8.53)
HBV coinfection 1.14 (0.70–1.85)
CD4+ count, per 50-cell increase 1.00 (0.94–1.07)
Unhealthy alcohol consumptiona 1.22 (0.81–1.86)
aUnhealthy alcohol use was defined as ±4 points in men and ±3 points in women on the Alcohol Use Disorders Identification Test-Consumption.
CI, confidence interval; WHO, World Health Organization; HBV, hepatitis B virus; BL, baseline; HIV, human immunodeficiency.
Figure 1. Treatment cascade for human immunodeficiency virus–infected adults with elevated blood pressure and taking
antiretroviral therapy in Lusaka, Zambia.
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CVEs may have been miscommunicated. Finally, an
urban cohort was studied, and thus the data may not
be generalizable to rural areas.
CVD will surpass infectious diseases as the leading
cause of death in Africa by 2030 [20], and HTN control
should be a major priority for public health on the
continent. These data demonstrate that although inte-
gration of BP screening and management in HIV care
settings was feasible in Zambia, virtually no patient had
optimal management of HBP. There is an especially
urgent need to test effective interventions to reduce
CVD risks among HIV-infected individuals.
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